80 related articles for article (PubMed ID: 27776647)
1. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.
Adams HJA; Kwee TC
Eur J Radiol; 2016 Nov; 85(11):1963-1970. PubMed ID: 27776647
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
Terasawa T; Dahabreh IJ; Nihashi T
Oncologist; 2010; 15(7):750-9. PubMed ID: 20587551
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/MR for diagnosis of primary central nervous system lymphoma: protocol for a systematic review and meta-analysis.
Qiu X; Zheng H; Zhong F; Shen B
BMJ Open; 2024 May; 14(5):e081458. PubMed ID: 38806425
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma.
Hosein PJ; Lossos IS
European J Clin Med Oncol; 2010 Feb; 2(1):131-138. PubMed ID: 22140415
[TBL] [Abstract][Full Text] [Related]
6. Refractory Burkitt Lymphoma With False-positive and False-negative Mass Detected on Positron Emission Tomography-computed Tomography After Chemotherapy.
Shima H; Takaki T; Ito J; Iwabuchi Y; Nakazawa A; Shimada H
J Pediatr Hematol Oncol; 2023 Oct; 45(7):e915-e916. PubMed ID: 37526341
[TBL] [Abstract][Full Text] [Related]
7. Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).
Hasani N; Paravastu SS; Farhadi F; Yousefirizi F; Morris MA; Rahmim A; Roschewski M; Summers RM; Saboury B
PET Clin; 2022 Jan; 17(1):145-174. PubMed ID: 34809864
[TBL] [Abstract][Full Text] [Related]
8. Expression of Concern: Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis.
PLOS ONE Editors
PLoS One; 2023; 18(10):e0292986. PubMed ID: 37819892
[No Abstract] [Full Text] [Related]
9. Corrigendum to: Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.
Neuro Oncol; 2024 Jun; 26(6):1174. PubMed ID: 38718145
[No Abstract] [Full Text] [Related]
10. Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis.
Adams HJA; Kwee TC
Crit Rev Oncol Hematol; 2019 Sep; 141():73-81. PubMed ID: 31252322
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Positive Results of
Dai N; Cai R; Deng S; Sang S
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370922
[TBL] [Abstract][Full Text] [Related]
12. Direct co-registration of [
Debacker JM; Maris L; Cordier F; Creytens D; Deron P; Descamps B; D'Asseler Y; De Man K; Keereman V; Libbrecht S; Schelfhout V; Van de Vijver K; Vanhove C; Huvenne W
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2127-2139. PubMed ID: 36854863
[TBL] [Abstract][Full Text] [Related]
13. No difference in treatment outcome between patients with nodal versus extranodal diffuse large B-cell lymphoma.
Khan SR; Muhammad A; Soomar SM; Shoaib D; Arshad Ali A; Muhammad T; Zahir MN; Abdul Jabbar A; Abdul Rashid Y; Heger M; Moosajee MS
J Clin Transl Res; 2023 Feb; 9(1):37-49. PubMed ID: 36687299
[TBL] [Abstract][Full Text] [Related]
14. End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET.
Chohan KL; Young JR; Lester S; Moustafa MA; Rosenthal A; Tun HW; Hoppe BS; Johnston PB; Micallef IN; Habermann TM; Ansell SM
Haematologica; 2023 Jun; 108(6):1697-1701. PubMed ID: 36546451
[No Abstract] [Full Text] [Related]
15. PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies.
Salem AE; Shah HR; Covington MF; Koppula BR; Fine GC; Wiggins RH; Hoffman JM; Morton KA
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497423
[TBL] [Abstract][Full Text] [Related]
16. Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report.
Kurch L; Georgi TW; Monecke A; Seehofer D; Borte G; Sabri O; Kluge R; Heyn S; Pierer M; Platzbecker U; Kayser S
Front Oncol; 2021; 11():798757. PubMed ID: 35117998
[TBL] [Abstract][Full Text] [Related]
17. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
Dai N; Liu H; Deng S; Sang S; Wu Y
Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
[No Abstract] [Full Text] [Related]
18. Whole-body MRI versus an [
Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; de Keizer B; Nievelstein RAJ
Eur Radiol; 2021 Dec; 31(12):8925-8936. PubMed ID: 34021390
[TBL] [Abstract][Full Text] [Related]
19. Biological Evaluation of [
Lin L; Xiang X; Su S; Liu S; Xiong Y; Ma H; Yuan G; Nie D; Tang G
Front Chem; 2021; 9():630452. PubMed ID: 33937189
[No Abstract] [Full Text] [Related]
20. Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions.
Tokola S; Kuitunen H; Turpeenniemi-Hujanen T; Kuittinen O
Cancer Med; 2021 May; 10(9):3035-3044. PubMed ID: 33792190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
